Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

This educational activity reviews currently approved prophylaxis therapy in hemophilia A, the benefits of prophylaxis and adherence, and patient quality-of-life factors. Interprofessional perspectives from an expert faculty panel are featured.

Faculty

Miguel A. Escobar, MD
Medicine and Pediatrics at the University of Texas Health Science Center
Gulf States Hemophilia & Thrombophilia Center
Houston, Texas

Cindy Leissinger, MD
Tulane University School of Medicine
the Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Guy Young, MD
the Hemostasis & Thrombosis Center
Children’s Hospital Los Angeles
the University of Southern California, Keck School of Medicine
Los Angeles, California

This activity is supported by an educational grant from Genentech, a member of the Roche Group

Continuing Education Information: Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

Read More

Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

Read More